STOCK TITAN
  1. Home
  2. Sec-filings
  3. MEDP
  4. [Form 4] Medpace Holdings, Inc. Insider Trading Activity

Insider sale: Medpace CEO reports MEDP stock trades near $591

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) CEO, director and 10% owner August J. Troendle reported selling common stock in two transactions in November 2025. On November 18, 2025, he sold 7,191 shares at a weighted average price of $590.84, leaving 886,177 shares owned directly. On November 19, 2025, he sold an additional 23,862 shares at a weighted average price of $592.07, leaving 862,315 shares owned directly.

The filing notes these trades were executed under a limit order during an open trading window and that prices reflect multiple trades within disclosed ranges. Troendle also reports indirect beneficial ownership of 4,733,019 shares held by Medpace Investors, LLC, where he is the sole manager and controlling unitholder, while formally disclaiming beneficial ownership beyond his economic interest.

Positive

  • None.

Negative

  • None.
Insider Troendle August J.
Role CEO
Sold 31,053 shs ($18.38M)
Type Security Shares Price Value
Sale Common Stock 23,862 $592.07 $14.13M
Sale Common Stock 7,191 $590.84 $4.25M
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 862,315 shares (Direct); Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)
Footnotes (1)
  1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $592.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $594.065. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Troendle August J.
(Last) (First) (Middle)
C/O MEDPACE HOLDINGS, INC.
5375 MEDPACE WAY
(Street)
CINCINNATI OH 45227
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/18/2025 S(1) 7,191 D $590.84(2) 886,177 D
Common Stock 11/19/2025 S(1) 23,862 D $592.07(3) 862,315 D
Common Stock 4,733,019 I By Medpace Investors, LLC(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $592.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $594.065. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Remarks:
/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle 11/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Medpace (MEDP) report in this Form 4?

The Form 4 reports that August J. Troendle, Medpace's CEO, director and 10% owner, sold Medpace common stock in two separate transactions on November 18 and 19, 2025.

How many Medpace (MEDP) shares did August J. Troendle sell and at what prices?

He sold 7,191 shares on November 18, 2025 at a weighted average price of $590.84 and 23,862 shares on November 19, 2025 at a weighted average price of $592.07.

How many Medpace (MEDP) shares does August J. Troendle own after these sales?

After the reported transactions, Troendle directly owns 862,315 Medpace shares and indirectly reports beneficial ownership of 4,733,019 shares held by Medpace Investors, LLC.

How were the sale prices for the Medpace (MEDP) insider transactions determined?

The filing states the reported prices are weighted average prices from multiple trades. On November 18, trades ranged from $590.00 to $592.09, and on November 19 from $590.00 to $594.065.

What is Medpace Investors, LLC and how does it relate to Medpace (MEDP) shares?

Medpace Investors, LLC ("MPI") holds 4,733,019 Medpace shares. Troendle is MPI's sole manager and controlling unitholder with voting and investment control and may be deemed to beneficially own these shares, while disclaiming ownership except for his pecuniary interest.

Were the Medpace (MEDP) insider sales made under a specific trading instruction?

The explanation notes the transactions were effected pursuant to a limit order placed by the reporting person during an open window period.